Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Friedland

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Diagnostic Microbiology and Infectious Disease|October 23, 2012
In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumoniaKevin M Krause, Johanne Blais, Stacey R Lewis, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniaeScott A Van Wart, Paul G Ambrose, Christopher M Rubino, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaDonald E Low, Thomas M File, Paul B Eckburg, et al.
Nucleic Acids Research|June 14, 2024
Formation of left-handed helices by C2'-fluorinated nucleic acids under physiological salt conditionsRoberto El-Khoury, Cristina Cabrero, Santiago Movilla, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2012
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infectionsH David Friedland, Tanya O'Neal, Donald Biek, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
Archives of Dermatology|August 18, 2010
Association of hearing loss with PHACE syndromeKelly J Duffy, Christina Runge-Samuelson, Michelle L Bayer, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal ImpairmentRichard A Preston, Grigor Mamikonyan, Stephane DeGraff, et al.
American Journal of Clinical Oncology|October 4, 2005
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancerKhalid Matin, Samuel A Jacobs, Thomas Richards, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Diagnostic Microbiology and Infectious Disease|October 23, 2012
In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumoniaKevin M Krause, Johanne Blais, Stacey R Lewis, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniaeScott A Van Wart, Paul G Ambrose, Christopher M Rubino, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaDonald E Low, Thomas M File, Paul B Eckburg, et al.
Nucleic Acids Research|June 14, 2024
Formation of left-handed helices by C2'-fluorinated nucleic acids under physiological salt conditionsRoberto El-Khoury, Cristina Cabrero, Santiago Movilla, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2012
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infectionsH David Friedland, Tanya O'Neal, Donald Biek, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
Archives of Dermatology|August 18, 2010
Association of hearing loss with PHACE syndromeKelly J Duffy, Christina Runge-Samuelson, Michelle L Bayer, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2018
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal ImpairmentRichard A Preston, Grigor Mamikonyan, Stephane DeGraff, et al.
American Journal of Clinical Oncology|October 4, 2005
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancerKhalid Matin, Samuel A Jacobs, Thomas Richards, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Pageof 6